- Home
- EIC vs SLGL Comparison
EIC vs SLGL Comparison
Compare EIC & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EIC | SLGL |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.8M | 247.1M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | EIC | SLGL |
|---|---|---|
| Price | $9.99 | $77.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $12.63 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 126.0K | 48.6K |
| Earning Date | 05-27-2026 | 05-22-2026 |
| Dividend Yield | ★ 13.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $223.84 |
| P/E Ratio | $9.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.17 | $0.62 |
| 52 Week High | $14.80 | $97.97 |
Technical Indicators
Market Signals| Indicator | EIC | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 60.22 | 50.32 |
| Support Level | $9.78 | $70.31 |
| Resistance Level | $10.15 | $84.75 |
| Average True Range (ATR) | 0.19 | 5.26 |
| MACD | 0.04 | 0.25 |
| Stochastic Oscillator | 65.75 | 43.88 |
Price Performance
Historical ComparisonAbout EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.